Valeant (VRX) PT Cut to $33 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM EDTLAVAL, Quebec, June 7, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, an increase of 9% versus the first quarter of 2015 (restated) GAAP EPS ($1.08); Adjusted EPS (non-GAAP) $1.27 GAAP Cash Flow from Operations was $558 million, an increase of 14% versus the first quarter of 2015 (restated) Updated Full Year 2016 Guidance: Total Revenue updated to $9.9 - $10.1 billion from $11.0 - $11.2 billion Adjusted EPS (non-GAAP) updated to $6.60 - $7.00 from $8.50 - $9.50 Adjusted EBITDA (non-GAAP) is updated to $4.80 - $4.95 billion from $5.60 - $5.80 billionValeant Pharmaceuticals International,... More
